Drugs / E7386
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT05607537 | Oct 2022 → Aug 2023 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04840927 | Apr 2021 → May 2023 | — | Eisai Inc. | Withdrawn | No outcome recorded |
| Phase 1 | NCT03996226 | Jun → Oct 2019 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03833700 | Mar 2019 → Mar 2027 expected | colorectal neoplasm | Eisai Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03264664 | Jul 2017 → Mar 2027 expected | neoplasm | Eisai Inc. | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05091346 | Oct 2021 → Oct 2024 | colorectal neoplasm, hepatocellular carcinoma, melanoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT04008797 | Jul 2019 → Mar 2027 expected | colorectal cancer, endometrial cancer, hepatocellular carcinoma | Eisai Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E7386 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05607537 ↗ |
| Action | Inhibit | “BACKGROUND: We present data from the Phase 1 open-label Study 101 of E7386, an oral protein-protein interaction inhibitor reported to block the CBP/β-catenin interaction, in...” PMID 42243349 ↗ Jun 2026 |
| Modality | Small molecule | “E7386, a novel small-molecule inhibitor, has been shown to enhance anti-angiogenesis when combined with lenvatinib.” PMID 40318924 ↗ Apr 2025 |
| Route | Oral | “E7386 will be administered as a single agent orally” NCT03264664 ↗ |